Clinical decisions for chronic myeloid leukemia in the imatinib era

被引：20

作者：

Goldman, JM ^{[1
]}

Marin, D ^{[1
]}

Olavarria, E ^{[1
]}

Apperley, JF ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London W12 0NN, England

来源：

SEMINARS IN HEMATOLOGY | 2003年 / 40卷 / 02期

关键词：

D O I：

10.1053/shem.2003.50049

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：98 / 103

页数：6

共 34 条

[1] UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE
ALLAN, NC
RICHARDS, SM
SHEPHERD, PCA
[J]. LANCET, 1995, 345 (8962) : 1392 - 1397
[2] Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders
Bonifazi, F
de Vivo, A
Rosti, G
Guilhot, F
Guilhot, J
Trabacchi, E
Hehlmann, R
Hochhaus, A
Shepherd, PCA
Steegmann, JL
Kluin-Nelemans, HC
Thaler, J
Simonsson, B
Louwagie, A
Reiffers, J
Mahon, FX
Montefusco, E
Alimena, G
Hasford, J
Richards, S
Saglio, G
Testoni, N
Martinelli, G
Tura, S
Baccarani, M
[J]. BLOOD, 2001, 98 (10) : 3074 - 3081
[3] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Branford, S
Rudzki, Z
Walsh, S
Grigg, A
Arthur, C
Taylor, K
Herrmann, R
Lynch, KP
Hughes, TP
[J]. BLOOD, 2002, 99 (09) : 3472 - 3475
[4] Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
Craddock, C
Szydio, RM
Klein, JP
Dazzi, F
Olavarria, E
van Rhee, F
Pocock, C
Cwynarski, K
Apperley, JF
Goldman, JM
[J]. BLOOD, 2000, 96 (01) : 86 - 90
[5] CROSS NCP, 1993, BLOOD, V82, P1929
[6] Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
Dazzi, F
Szydlo, RM
Craddock, C
Cross, NCP
Kaeda, J
Chase, A
Olavarria, E
van Rhee, F
Kanfer, E
Apperley, JF
Goldman, JM
[J]. BLOOD, 2000, 95 (01) : 67 - 71
[7] Delannoy A, 1997, J NATL CANCER I, V89, P1616
[8] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
Druker, BJ
Sawyers, CL
Kantarjian, H
Resta, DJ
Reese, SF
Ford, JM
Capdeville, R
Talpaz, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1038 - 1042
[9] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker, BJ
Talpaz, M
Resta, DJ
Peng, B
Buchdunger, E
Ford, JM
Lydon, NB
Kantarjian, H
Capdeville, R
Ohno-Jones, S
Sawyers, CL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1031 - 1037
[10] Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Druker, BJ
Lydon, NB
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) : 3 - 7

← 1 2 3 4 →